CURRICULUM VITAE

**WILLIAM DOUGLAS FIGG, SR**

**Work Address:** National Institutes of Health

National Cancer Institute

Center for Cancer Research

Medical Oncology Branch

Molecular Pharmacology Section

Building 10, Room 5A01, MSC 1910

9000 Rockville Pike

Bethesda, Maryland 20892

Telephone (301) 402-3623

Mobile (240) 338-6898

Fax (301) 402-8606

Email wdfigg@helix.nih.gov

**Education:**

8/81 - 5/83Georgetown College, Georgetown, Kentucky,

Major - Biology

8/83 - 11/86Samford University, School of Pharmacy, Birmingham, AL

**Bachelor of Science**

9/87 - 8/89Auburn University, School of Pharmacy, Birmingham, AL

**Doctor of Pharmacy**

5/01 - 7/03Columbia University, School of Business, New York, NY and

London Business School, University of London, London, UK,

**Master of Business Administration**

**Post-Graduate Training:**

11/86 - 9/87Internship, University of Alabama Hospital, Birmingham, AL

6/90 - 6/92Post-Doctoral Fellowship in Clinical Research/Drug Development,

University of North Carolina at Chapel Hill, Chapel Hill, NC

Revised – 10 July 2008

**Professional Appointments:**

6/83 - 11/86Pharmacy Externship, Department of Pharmacy,

BMC Princeton Hospital, Birmingham, Alabama (20 hrs/wk)

9/87 - 6/90Clinical Pharmacist, Department of Pharmacy, University of

Alabama Hospital, Birmingham, Alabama

6/90 - 6/92Clinical Staff Pharmacist,Department of Pharmacy,

Duke University Medical Center, Durham, North Carolina

(12-20 hrs/wk)

7/92 - 7/95Clinical Pharmacist, Pharmacy Department,Mary Washington

Hospital, Fredericksburg, Virginia (8 hrs/wk)

7/92 - 8/93Clinical Investigator, Clinical Pharmacokinetics Section,

Clinical Pharmacology Branch, National Cancer Institute,

Bethesda, Maryland

7/92 - presentSenior Staff, Prostate Cancer Clinic, National Cancer Institute,

Bethesda, Maryland

9/93 - 12/96Senior Investigator, Section Head, Clinical Pharmacokinetics

Section, CPB, DCS, NCI; and Deputy Branch Chief, Clinical

Pharmacology Branch, Division of Clinical Sciences, National

Cancer Institute, Bethesda,Maryland

12/96 - 2/01Senior Investigator and Head, Clinical Pharmacokinetics Section,

Developmental Therapeutics Department, Medicine Branch, Division

of Clinical Sciences, National Cancer Institute, Bethesda, Maryland

2/01-11/05Principle Investigator and Head of the Molecular Pharmacology

Section, Cancer Therapeutics Branch, Center for Cancer Research,

National Cancer Institute; and Head of the Clinical Pharmacology

Scientific Core, Medical Oncology Clinical Research Unit, CCR,

NCI; and Head of the Preclinical Pharmacokinetics Core, Molecular

Targets Program, CCR, NCI

11/05 - presentSenior Scientist and Head of the Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute; and Head of the Clinical Pharmacology Program, MOB, CCR, NCI; and Head, Biological Fluid Processing Core, CCR, NCI, National Institutes of Health, Bethesda, Maryland

**Professional Licensure:**Alabama State Board of Pharmacy #11217 (15 Sept 1987)

Tennessee State Board of Pharmacy #007039 (21 May 1987)

North Carolina State Board of Pharmacy #11089 (18 Sept 1990)

Virginia State Board of Pharmacy #0202011192 (19 Oct 1993)

**Board Certification:**Pharmacotherapy Specialty #291192 (8/91)

recertification 12/99

recertification 12/07

**Academic Appointments/Affiliations/Teaching Responsbilities:**

Lecturer - Howard University Pharm.D. Program (Oncology Module in Therapeutics course), 1995

Lecturer - Shenandoah University Pharm.D. Program

(Oncology Module in Therapeutics course), (1999-2000)

Graduate Advisor - University of Pittsburgh School of Pharmacy, School of Pharmacy (1996-1999)

Adjunct Professor - University of Maryland School of Pharmacy (1994-present)

Adjunct Clinical Professor – University of Kentucky School of Pharmacy (1993–1999)

Clinical Pharmacology Consultant – Johns Hopkins University (1999–2000)

Adjunct Clinical Associate Professor – University of Michigan School of Pharmacy (2003–present)

Affiliate Professor and Graduate Advisor - Virginia Commonwealth University,

Medical College of Virginia, School of Pharmacy, Department of Pharmaceutics (1997-present)

Lecturer – Columbia University, School of Public Health,

Course - Strategic Management and Healthcare Policy (2004-2007)

Graduate Advisor – Oxford University (2005 – present)

Graduate Advisor – George Washington University, Department of Genetics (2004 – present)

Graduate Advisor – University of Maryland, Molecular and Cell Biology Program (2006 – present)

Graduate Advisor – Johns Hopkins University (2008 – present)

**United State Public Health Service Commissioned Corps.:**

US Public Health Service Commissioned Officer 0-3 (Lt.), 7/92-12/93

US Public Health Service Commissioned Officer 0-4 (Lt. Commander), 1/94 - 12/98

US Public Health Service Commissioned Officer 0-5 (Commander), 1/99 – 6/06

US Public Health Service Commendation Medal, 1995

US Public Health Service Commissioned Corps Unit Commendation, 2004

US Public Health Service Commissioned Corps Bicentennial Unit Commendation, 1998

US Public Health Service, Pharmacy Professional Advisory Committee (1997 - 2000)

Subcom. on Pharmaceutical Care (1995 - 1998)

Chair, Subcommittee on Pharmaceutical Care (1998 - 2000)

Liason to ACCP (2005 – present)

US Public Health Services Commissioned Corps Medical Review Board (2002)

US Public Health Commissioned Corps Readiness Force

Basic Response Readiness Certified (2005 – present)

US Public Health Commissioned Corps Assimilation into the Regular Corps, 2007

Deployed to Meridian, Mississippi in Response to Hurricane Katrina –

Command Staff, Head of Logistics

US Public Health Service Commissioned Corps Citation Medal, 2005

US Public Health Service Commissioned Corps Crisis Response Service Award

Gulf Coast Hurricanes, 2005

US Public Health Service Commissioned Officer 0-6 (Captain), 7/06 – present

US Public Health Service Commissioned Corps Citation Medal, 2006

US Public Health Service Commissioned Corps Commendation Medal, 2006

US Public Health Service Commissioned Corps OCCO Board (one year appointment)

US Public Health Service Commissioned Corps Functional Group Transformation Team

(Research Category)

US Public Health Service Commissioned Corps Outstanding Unit Citation, 2007

**Professional Affiliations:**

American Society of Health-System Pharmacist (1986 – 1992, 2005 - present)

Abstract Reviewer (1992-2001)

American College of Clinical Pharmacy (1990 - present)

Research Affairs Committee (1992 - 1994)

Chairman of Abstract Selection Committee (1997)

Abstract Reviewer for Oncology Submission (1996 - present)

Program Committee, 1997 Annual Meeting

Awards Committee (1997-1999)

Chair, Subcommittee on the Young Investigator’s Award (1998-1999)

Task Force on Science (1999 - 2001)

Fellowship Credential Committee (2001 - 2002)

Research Institute Trustee – Elected member (2003 – 2006)

Chair, Grants and Fellowship Selection Committee (2006)

American Society for Clinical Pharmacology and Therapeutics (1991 - present)

American College of Clinical Pharmacology (1992 - present)

Chairman Government Advisory Board (1995 - 1997)

Program Committee, 1999 Annual Meeting

Abstract Reviewer (1999)

American Association for Cancer Research (1993 - present)

EORTC/NCI/AACR program committee (2007)

Abstract Reviewer EORTC/NCI/AACR meeting (2007)

Scientific Committee 20th EORTC/NCI/AACR Molecular Targets and

Cancer Therapeutics Symposium

American Society of Clinical Oncology (1993 - present)

Abstract Reviewer (2000)

Program Committee (2000)

American Urological Association (1998 - present)

Association of Military Surgeons of the US (1998 - present)

American Association of Pharmaceutical Science (2005 – present)

American Pharmacists Association (2005 – present)

Hematology/Oncology Pharmacy Association (2005 – present)

**Professional Activities/Committees (intramural and extramural):**

National Institutes of Health, Pharmacy and Therapeutics Committee,

NCI Representative (1994 - present)

Board of Pharmacotherapy Specialty, Item Writer for Exam (1991 - 1994)

National Association of Boards of Pharmacy Licensure Examination, Item Writer (1996)

Howard Hughes Medical Institute Scholars Program, Selection Committee (1996, 1998)

Advisory Comm. for Endocrinology Section, National Institute of Child Health and

Human Development (1997)

Head, Clinical Pharmacology Special Interest Group, National Institutes of Health (1997 - 1998)

Head, Clinical Pharmacology Special Interest Subgroup in Oncology (1998 - 2002)

NCI’s Prostate Cancer Task Force (1997 - 1998)

NCI’s Prostate Cancer Progress Review Group (1997 - 1998)

2003 Committee to Evaluate the progress of the 1998 Prostate PRG

Co-Chair, NCI’s Tumor Angiogenesis and Invasion Think Tank (1998 - 2002)

NCI's Ad Hoc Tenure and Promotion Committee Reviewer (1999)

American Association of Pharmaceutical Scientists - Visiting Scientist –

MCV School of Pharmacy (2000)

US Pharmacopeia, Scientific Advisory Board for Oncology (2000 - 2003)

NCI, CCR’s Early Drug Development Committee (2004 – 2005)

NCI, CCR’s Tissue Repository Committee (2004-2005)

NCI’s Protocol Monitoring and Review Committee, Ad Hoc Clinical Pharmacology Reviewer

(2000 - 2002)

NCI's Medical Oncology Branch Protocol Review Committee (1999 - 2001)

NCI's Cancer Therapeutics Branch Protocol Review Committee (2001 - 2005)

NCI’s Medical Oncology Branch Protocol Review Committee (2006 – present)

NCI's Vascular Biology Faculty – Steering Committee (2001 - present)

Co-Chair, NCI's Vascular Biology Faculty (2001 - 2004)

Chair, NCI’s Vascular Biology Faculty (2005 – 2006)

NCI's GU Malignancy Faculty – Steering Committee (2001 - present)

NCI's Molecular Target Faculty – Steering Committee (2002 - present)

NCI's Institutional Review Board (2002 - 2004)

NCI’s Technology Review Group (2005 – present)

NCI’s Joint Drug Development Committee, voting member (2005 – present)

NCI’s Pharmacodynamic Endpoint Meeting – Chaired (2006)

NCI’s Molecular Target Prioritization Meeting – Chaired (2006)

NCI’s Drug Development Prioritization Meeting – Chaired (2006)

NCI’s Medical Oncology Chief Search Committee (2006)

NIH’s Scientific Directors Ad Hoc Committee on Biological Samples (2006-2007)

NIH’s Clinical Pharmacology Program and Course – Steering Committee (2006 – present)

NCI’s Friday Medical Oncology Lecture Series (co-coordinator) (2005 - present)

NCI’s Prostate Cancer Teaching Conference (coordinator) (1987 – present)

NCI’s Molecular Target Development Program (review committee) 2007

2008 7th Annual NIH Oxford/Cambridge Colloqium – Program/Organizing Chair

NCI’s Molecular Targets Development Program – Chair of the Steering Committee

**Editorial Appointments/Activities:**

Assistant Editor1991-presentDrugDex Information Systems (MicroMedex)

Editorial Board1997-presentPharmacotherapy

External Advisory Board1994-2001Physician Data Query, Clinical Trial Database

Editorial Board1994-1997Oncology Report

Editorial Board1995-presentJournal of Clinical Pharmacology

Editorial Board1997-2001The Prostate Journal

Associate Editor1999-presentClinical Cancer Research

Editorial Board2000-presentThe Journal for Drug Evaluation

Editorial Board2000Pediatric Drug Therapy

Section Editor2000-2005Clinical Prostate Cancer

Editorial Board2001-presentCancer Biology and Therapy

Editorial Board2002-presentInternational Journal of Cancer

Editorial Board2002-presentMolecular Cancer Therapeutics

Editorial Board2004-presentCurrent Cancer Therapy Reviews

Editorial Board2005-presentJournal American Pharmacists Association

Editorial Board2005-presentRecent Patents on Anti-Cancer Drug Discovery

Editorial Board2006-presentClinical Genitourinary Cancer

Editorial Board2007-presentThe Open Cancer Letters

Reviewer:Journal of Chromatograph BPharmacogenetics

Investigational New DrugsAntimicrobial Agents and Chemotherapy

Southern Medical JournalAmerican Journal Pathology

Biochemical PharmacologyCancer Research

Annals of PharmacotherapyJournal of Oncology Pharmacy Practice

Cancer InvestigationJournal American Medical Association

British Journal of CancerJ of Pharmacokinetic and Pharmacodynamics

CancerJournal of National Cancer Institute

Analytica Chimica ActaJournal Clinical Investigation

LipidsAmerican Hospital Formulary Service

BiotechniquesMolecular Medicine Today

BloodTrends in Pharmacology Science

Molecular PharmacologyHuman Genetics

Clin Pharmacology TherapeuticsCancer Chemotherapy Pharmacology

FASEB LettersNature Cancer Review

Journal of UrologyThe Oncologist

Journal of Molecular MedicineUrology

J Pharmacology Exp TherapeuticsLaboratory Investigation

The Pharmacogenomic JournalCancer Epidemiology, Biomarkers and Prevention

Biol of Blood Marrow TransplJournal of Clinical Oncology

European Journal of CancerJournal of Pharmacy and Pharmacology

NeoplasiaIn Vitro Cellular and Developmental Biology

Journal of PathologyBritish Journal Hematology

Proc Natl Academy ScienceEuropean Urology

OncogeneLeukemia

Human MutationLife Sciences

LancetBioorganic & Medicinal Chemistry

**University Organizations/Activities:**

Golf Team - Georgetown College, 1982

Kappa Alpha - Georgetown College, 1982

Phi Delta Chi - Samford University, 1984

**Awards, Honors and Fellowships:**

Beta Beta Beta, Samford University, 1985

Outstanding Young Men of America, 1987

Glaxo Research Institute Fellowship, 1990-92

Recipient NIH Research Award - Student Loan Repayment, 1992-93

Who’s Who in the East, 1998, 1999, 2000

Who’s Who in America, 2000

1996 McKeen Cattell Award from American College of Clinical Pharmacology’s

Journal of Clinical Pharmacology (co-author)

1997 Fellow, American College of Clinical Pharmacy

2000 Fellow, American College of Clinical Pharmacology

2001 Allen J. Brands Clinical Pharmacist of the Year Award,

US Public Health Service Commissioned Officers Association

2003 Association of Military Surgeons of the United States,

Clinical Pharmacist of the Year Award

2003 Center for Cancer Research Federal Technology Transfer Award

2004 Ohio County High School, Hartford, KY – Alumni Professional Achievement Award

2003 US Navy, Meritorious Unit Commendation

2004 Academy of Medicine, Washington, DC – elected member

2004 Center for Cancer Research Federal Technology Transfer Award

2005 Leon I. Goldberg Young Investigator Award,

American Society of Clinical Pharmacology and Therapeutics

2005 19th Annual Singapore World Pharmacy Congress, Keynote Lecture and Award

2005 Center for Cancer Research Federal Technology Transfer Award

2006 Center for Cancer Research Federal Technology Transfer Award

2007 Center for Cancer Research Federal Technology Transfer Award

2007 The Annual Graduate Student Invited Lecture, Dartmouth College of Medicine, Department of

Pharmacology and Toxicology

2007 NVCA Teacher of the Year Award

2007 NIH Clinical Center Director’s Award

2008 Columbia University Business School Non-Profit Alumni Award

2008 Samford University School of Pharmacy – Commencement Address

2008 Russell R. Miller Award, American College of Clinical Pharmacy

**Executive Management Training:**

Johns Hopkins University, School of Business, Baltimore, MD,

Leadership and Organizational Behavior, 1994

Wharton School of Management, University of Pennsylvania, Philadelphia, PA,

Essentials of Management, 1998, 1999

**Certifications:**

Basic Life Support (1989 – present)

**Bibliography:**

Avent CK, Krinsky D, Kirklin JK, Bourge RC, **Figg WD**. Synergistic Nephrotoxicity Due to Ciprofloxacin and Cyclosporine. *Am J Med* 1988;85:452-3.

**Figg WD**. Cyclosporine-Induced Hyperuricemia and Gout. *N Engl J Med* (letter) 1990;322:334-5.

Thompson G, **Figg WD**. Diarrhea Precipitated by Oral Liquid Medication. *Am J Med* (letter) 1990;89:697.

Bourge RC, Kirklin JK, Naftel DC, **Figg WD**, Williams-White C, Ketchum C. Diltiazem-Cyclosporine Interaction in Cardiac Transplant Patients: Impact on Cyclosporine Dose and Medication Costs. *Am J Med* 1991;90:402-4.

**Figg WD**. Peripheral Neuropathy in HIV Patient after Isoniazid Therapy Initiated. *Annals of Pharmacotherapy* (letter) 1991;25:100-1.

**Figg WD**. Aseptic Meningitis Associated with Muromonab-CD3. *Annals of Pharmacotherapy* (letter) 1991;25:1395.

**Figg WD**. Ondansetron versus Dexamethasone. *Lancet* (letter) 1991;338:946.

Thibault A, **Figg WD**, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Anaphylactoid Reaction with Suramin.  *Pharmacotherapy* 1993;13:656-7.

Erratum: Annalphylactoid Reaction with Suram. *Pharmacotherapy* 1994;14:125.

**Figg WD**, Thibault A. Book Review: Oxford Textbook of Clinical Pharmacology and Drug Therapy. *Annals of Pharmacotherapy* 1993;27:797.

**Figg WD**, Graham CL, Hak LJ, Dukes GE. Ondansetron: A Novel Antiemetic Agent. *S Med J* 1993;86:497-502.

Thibault A, **Figg WD**. Book Review: Cancer of the Prostate. *J Natl Cancer Inst* 1993;85:1958-9.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, **Figg WD**, Linehan WM, Myers CE. Surprising Activity of Flutamide Withdrawal, When Combined with Aminoglutethimide, in Treatment of “Hormone-Refractory” Prostate Cancer. *J Natl Cancer Inst* 1994;86:222-7.

**Figg WD**, Yeh HJC, Thibault A, Pluda JM, Itoh F, Yarchoan R, Cooper MR. Assay of the AntiangiogenicCompound, TNP-470, and One of its Metabolites, AGM-1883, by Reversed-Phase High Performance Liquid Chromatography in Plasma. *J Chrom B* 1994;652:187-94.

Thibault A, Cooper MR, **Figg WD**, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE. A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer. *Cancer Res* 1994;54:1690-4.

Thibault A, **Figg WD**, McCall NA, Samid D, Myers CE, Cooper MR. A Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid and Phenylbutyric Acid, and One of Their Metabolites, Phenylacetylglutamine, by Reversed-Phase, High Performance Liquid Chromatography. *J Liq Chrom* 1994;17:2895-900.

**Figg WD**, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Hypothyroidism Associated with Aminoglutethimide in Patients with Prostate Cancer. *Arch Int Med* 1994;154:1023-5.

**Figg WD**, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. *In Vitro* Antitumor Effect of Hydroxyurea on Hormone-Refractory Prostate Cancer Cells and its Potentiation by Phenylbutyrate. *Anti-Cancer Drugs* 1994;5:336-42.

**Figg WD**, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Acute Renal Toxicity Associated with Suramin in the Treatment of Prostate Cancer. *Cancer* 1994;74:1612-4.

Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson MA, Jaffe ES, **Figg WD**, Tompkins A, Bastian A, Nylen P, Woodworth T, Udey MC, Sausville EA. Chimeric Fusion Protein Toxin DAB486IL-2 in Advanced Mycosis Fungoides and the Sezary Syndrome: Correlation of Activity and Interleukin-2 Receptor Expression in a Phase II Study. *Blood* 1994;84:1765-74.

**Figg WD**, Stevens JA, Cooper MR. Adaptive Control With Feedback of Suramin Using Intermittent Infusions. *J Clin Oncol* (letter) 1994;12:1523-4.

**Figg WD**. Angiogenesis: A Therapeutic Target for Tumor Suppression. *Issues in Pharmacotherapy*  1994;14:3.

**Figg WD**, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Prostate Specific Antigen Decline Following the Discontinuation of Flutamide in Patients with Stage D2 Prostate Cancer. *Am J Med* 1995;98:412-4.

**Figg WD**, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, Hak LJ. Comparison of Quantitative Methods to Assess Hepatic Function: Pugh’s Classification, Indocyanine Green, Antipyrine, and Dextromethorphan. *Pharmacotherapy* 1995;15:693-700.

Thibault A, Samid D, Cooper MR, **Figg WD**, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I Study of Phenylacetate Administered Twice Daily to Patients with Cancer. *Cancer* 1995;75:2932-8.

Piscitelli SC, Thibault A, **Figg WD**, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. *J Clinical Pharmacology* 1995;35:368-73.

**Figg WD**, McCall NA, Reed E, Sartor O. The *in vitro* Response of Four Antisteroid Receptor Agents on the Hormone-Responsive Prostate Cancer Cell Line LNCaP.  *Oncol Report* 1995;2:295-8.

Bitton RJ, **Figg WD**, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Pharmacologic Variables Associated with the Development of Neurologic Toxicity in Patients Treated with Suramin. *J Clin Oncol* 1995;13:2223-9.

**Figg WD**, Middleman MN, Sartor O. Mutated Androgen Receptors of Prostate-Cancer Cells. *N Engl J Med* (letter) 1995;333:1010.

**Figg WD**, Thibault A, Cooper MR, Reid B, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. A Phase I Study of the Somatostatin Analogue Somatuline in Patients with Metastatic Hormone-Refractory Prostate Cancer. *Cancer* 1995;75:2159-64.

McCall NA, Samid D, **Figg WD**. Stability of Sodium Phenylacetate and Sodium Phenylbutyrate in Parenteral Large-Volume Sterile Water. *Drug Stability* 1995;1:54-8.

Danesi R, **Figg WD**, Reed E, Myers CE. Paclitaxel (Taxol®) Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human Prostate Cancer Cells. *Mol Pharmacol* 1995;47:1106-11.

Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, **Figg WD**, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr J, Wittes RE, Vitetta ES. Continuous Infusion of the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients with B-Cell Lymphoma: A Phase I Study. *Blood* 1995;85:3457-65.

**Figg WD**, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob J, Boudoulas S, Goldspiel B, Sarosy G, Liotta LA, Kohn EC. Pharmacokinetics of Orally Administered Carboxyamido-triazole, an Inhibitor of Calcium-mediated Signal Transduction. *Clin Cancer Res* 1995;1:797-803.

Dawson NA, Cooper MR, **Figg WD**, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor Activity of Suramin in Hormone-Refractory Prostate Cancer Controlling for Hydrocortisone Treatment and Flutamide Withdrawal as Potentially Confounding Variables. *Cancer* 1995;76:453-62.

Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Prolonged Response to Flutamide Withdrawal and Initiation of Aminoglutethimide in a Patient with Metastatic Prostate Cancer. *J Oncol Pharm Practice* 1995;1:45-7.

Guetta V, Lush RM, **Figg WD**, Waclawiw MA, Cannon RO. Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women. *Am J Cardiology* 1995;76:1072-3.

Bitton RJ, **Figg WD**, Reed E. A Preliminary Risk-Benefit Assessment of Paclitaxel. *Drug Safety* 1995;12:196-208.

Bowden CJ, **Figg WD**, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. A Phase I/II Study of Continuous Infusion Suramin in Patients with Hormone-Refractory Prostate Cancer: Toxicity and Response. *Cancer Chemother Pharmacology* 1996;39:1-8.

Sartor O, **Figg WD**. Mifepristone: Antineoplastic Studies. In Pitkin RM, Scott JR (Editors) Clinical Obstetrics and Gynecology. Published by Lippincott-Raven, Philadelphia, PA, 1996:498-505.

**Figg WD**, Middleman MN, Sartor O. Therapeutic Options in Patients with Hormone-Refractory Prostate Cancer. *American J Med* (letter) 1996;100:243-4.

Tisdale JF, **Figg WD**, Reed E, McCall NA, Alkins BR, Horne MK. Severe Thrombocytopenia in Patients Treated with Suramin: Evidence for an Immune Mechanism in One. *Am J Hematol* 1996;51:152-7.

**Figg WD**, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O. Lack of Correlation Between Prostate Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer. *Cancer Invest* 1996:14:513-7.

Lush RM, Nguyen BY, Cundy KC, Bauza S, Sogocio T, Stevens J, Piscitelli S, Venzon D, Yarchoan R, **Figg WD**. Pharmacokinetics of (s)-9-(2-Phosphonylmethoxyethyl)adenine (PMEA) and when Administered in Combination with Zidovidine (AZT). *J Applied Ther* 1996;1:13-8.

Walls R, Thibault A, Lui L, Wood C, Kozlowski JM, **Figg WD**, Sampson ML, Elin RJ, Samid D. The Differentiating Agent Phenylacetate Increases Prostate-Specific Antigen Production by Prostate Cancer Cells. *The Prostate* 1996;29:177-82.

Walther MM, **Figg WD**, Linehan WM. Intravesical Suramin: A Novel Agent for the Treatment of Superficial Transitional-Cell Carcinoma of the Bladder. *World J Urol* 1996;14:S8-S11.

Middleman MN, Lush RM, **Figg WD**. The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate. *Pharmacotherapy* 1996;16:376-81.

Lush RM, **Figg WD**, Pluda JM, Bitton R, Headlee D, Kohler D, Reed E, Sartor O, Cooper MR. A Phase I Study of Pentosan Polysulfate Sodium in Patients with Advanced Malignancies. *Annals of Oncology* 1996;7:939-44.

Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Treatment Approaches for Metastatic Cancer of the Prostate based on Recent Molecular Evidence. *Cancer Treatment Rev* 1996;22:105-18.

Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, **Figg WD**, Davis PA, Jacob J, Goldspiel B, Liotta L. Clinical Investigation of a Cytostatic Calcium Influx Inhibitor in Patients with Refractory Cancer. *Cancer Res* 1996;56:569-73.

Thibault A, Samid D, Tompkins AC, **Figg WD**, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in Patients with Cancer. *Clin Cancer Res* 1996;2:483-91.

**Figg WD**, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, Songer SS, Powell JR, Hak LJ. Pharmacokinetics of Ondansetron in Patients with Hepatic Insufficiency. *J Clinical Pharmacology* 1996;36:206-15.

**Figg WD**, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz A, Steinberg SM, Tompkins A, Reed E, Sartor O. Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer. *Acta Oncol* 1996;35:763-5.

Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, **Figg WD**. Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents. *Ther Drug Monit* 1996;18:714-20.

Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, **Figg WD**. Suramin-Induced Neutropenia. *Eur J Cancer* 1996;32A:1534-9.

Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, **Figg WD**, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. A Phase I Study of Bolus vs. Continuous Infusion of the Anti-CD19 Immunotoxin, IgG-HD37-dgA in Patients with B Cell Lymphoma. *Blood* 1996;88:1188-97.

Simmons BR, Bauer KS, McCall NA, Kohn EC, **Figg WD**. An optimized Method for the Quantitation of Carboxyamido-triazole (CAI) in Human Plasma with Solid Phase Extraction and Reverse Phase HPLC. *Analy Let* 1996;30:2009-21.

Lush RM, **Figg WD**. Book Review: Principles of Antineoplastic Drug Development and Pharmacology. *Annals Pharmacotherapy* 1997;31:377.

Dixon SC, Soriano BJ, Lush RM, Borner MM, **Figg WD**. Apoptosis: Its Role in the Development of Malignancies and Its Potential as a Novel Therapeutic Target. *Annals Pharmacotherapy* 1997;31:76-82.

Piscitelli SC, Reiss WG, **Figg WD**, Petros WP. Pharmacokinetic Studies with Recombinant Cytokines: Scientific Issues and Practical Considerations. *Clinical Pharmacokinetic* 1997;32:368-81.

**Figg WD**, Feuer J, Bauer KS. Management of Hormone-Sensitive Metastatic Prostate Cancer. *Cancer Practice* 1997;5:258-263.

Masiero L, **Figg WD**, Kohn EC. New Anti-angiogenesis Agents: Review of Experience with Carboxyaminido-triazole (CAI), Thalidomide, TNP-470, and interleukin-12. *The Angiogenesis J* 1997;1:23-35.

**Figg WD**, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E, Yarchoan R. The Pharmacokinetics of TNP-470, A New Angiogenesis Inhibitor.  *Pharmacotherapy* 1997;17:91-7.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, **Figg WD**. Initial Pharmacokinetics and Bioavailability of PSC 833, a P-Glycoprotein Antagonist. *J Clinical Pharmacology* 1997;37:123-8.

**Figg WD**, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E. Pharmacokinetics of Elemental Platinum (Ultrafiltrate and Total) After a Thirty Minute Intravenous Infusion of Ormaplatin. *Biopharm Drug Disp* 1997;18:347-359.

Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, **Figg WD**. Pharmacometric Analysis of the Effect of Furosemide on Suramin Pharmacokinetics. *Pharmacotherapy* 1997;17:431-7.

Walsh TJ, Whitcomb T, Piscitelli S, **Figg WD**, Hill S, Chanock SJ, Jarosinski P, Gupta R, Pizzo PA. Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex in Children with Hepatosplenic Candidiasis. *Antimicrob Agents Chemother* 1997;41:1944-8.

Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, **Figg WD**, Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe E, Sausville EA. Complete Sustained Response of a Refractory Post-Transplantation, Large B-cell Lymphoma to an Anti-CD22 Immunotoxin. *Annals Internal Med* 1997;126:882-5.

Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, **Figg WD**, Venzon DJ, Alexander HR. A Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion with Tumor Necrosis Factor and Cisplatin in the Treatment of Peritoneal Carcinomatosis. *Cancer* 1998;83:1251-61. Ma GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti SK, Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J Sci Am* 1997;3:174-9.

Ma GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti SK, Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J Sci Am* 1997;3:174-9.

Simmons BR, Lush RM, **Figg WD**. A Reversed-Phase high performance liquid chromatography method using Solid Phase Extraction to Quantitate Thalidomide in Human Serum. *Analy Chim Acta* 1997;339:91-7.

Bergan RC, Walls R, **Figg WD**, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E. Similar Clinical Outcomes in African American and non-African American Males Treated with Suramin for Metastatic Prostate Cancer. *J Natl Med Assoc* 1997;89:622-8.

Dawson NA, **Figg WD**, Cooper MR, Sartor O, Bergan RC, Senderowicz A, Steinberg SM, Tompkins A, Weinberger BM, Sausville EA, Reed E, Myers CE. A Phase II Trial of Suramin, Leuprolide, and Flutamide in Previously Untreated Metastatic Prostate Cancer. *J Clin Oncol* 1997;15:1470-7.

**Figg WD**, Kroog G, Duray P, Walther MM, Patronas N, Sartor O, Reed E. Flutamide Withdrawal Plus Hydrocortisone Resulted in Clinical Complete Response in a Patient with Prostate Carcinoma. *Cancer* 1997;79:1964-8.

Dixon S, Zalles A, Giordano C, Venzon D, Lush RM, Reed E, **Figg WD**. In vitro Effect of Gallium Nitrate when combined with Ketoconazole in the Prostate Cancer Cell Line PC-3. *Cancer Letter* 1997;113:111-6.

Kohn EC, **Figg WD**, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Tompkins A, Liotta LA, Reed E. Phase I Trial of Micronized Formulation Carboxyamidotriazole in Patients with Refractory Solid Tumors: Pharmacokinetics, Clinical Outcome and Comparison of Formulations. *J Clinical Oncology* 1997;15:1985-93.

Piscitelli SC, **Figg WD**, Hahn B, Kelly G, Thomas S, Walker RE. Single-Dose Pharmacokinetics of Thalidomide in Human Immunodeficiency Virus-Infected Patients. *Antimicrob Agents Chemother* 1997;41:2797-9.

Dawson N, **Figg WD**, Brawley O, Bergan RC, Cooper MR, Senderowicz AM, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan M, Reed E, Sartor O. A Phase II Study of Suramin Plus Aminoglutethimide in Two Cohorts of Patients with Androgen-Independent Prostate Cancer: Simultaneous Antiandrogen Withdrawal and Prior Antiandrogen Withdrawal. *Clin Cancer Res* 1998;4:37-44.

Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, **Figg WD**, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R. Phase II Trial with Dose Titration of Paclitaxel for the Therapy of Human Immunodeficiency Virus-Associated Kaposi’s Sarcoma. *J Clinical Oncology* 1998;16:1112-21.

Thibault A, **Figg WD**, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. A Phase II Study of 5-Aza-2’-Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer. *Tumori* 1998;84:87-9.

Sartor O, Weinberger M, Moore A, Li A, **Figg WD**. Effect of Prednisone on Prostate-Specific Antigen in Patients with Hormone Refractory Progressive Prostate Cancer. *Urology* 1998;52:252-6.

Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, **Figg WD**. Elevated Carcinomembryonic Antigen in Patients with androgen-independent Prostate Cancer. *J Invest Med* 1998;46:66-72.

Bauer KS, Dixon SC, **Figg WD**. Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation which is Species-Dependent. *Biochem Pharmacology* 1998;55:1827-34.

Horti J, **Figg WD**, Weinberger B, Kohler D, Sartor O. A Phase II Study of Bromocriptine in Patients with Androgen Independent Prostate Cancer. *Oncology Report* 1998;5:893-6.

Dixon SC, Horti J, Guo Y, Reed E, **Figg WD**. Methods for Extracting and Amplifying Genomic DNA isolated from Frozen Serum. *Nature Biotechnol* 1998;16:91-4.

Alexander HR, Brown CK, Bartlett DL, Libutti SK, **Figg WD**, Raje S, Turner E. Augmented Capillary Leak During Isolated Hepatic Perfusion (IHP) Occurs Via Tumor Necrosis Factor Independent Mechanisms. *Clin Cancer Res* 1998;4:2357-62.

Sausville EA, Lush RM, Headlee D, Smith AC, **Figg WD**, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Clinical Pharmacology of UCN-01: Initial Observations and Comparison to Preclinical Models. *Cancer Chemother Pharmacol* 1998;42(Suppl)S54-9.

Piscitelli SC, Vogel S, **Figg WD**, Raje S, Forrest A, Metcalf JA, Baseler M, Falloon J. Alteration in Indinavir Clearance During Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. *Pharmacotherapy* 1998;18:1212-6.

**Figg WD**, Kim G. The Role of Angiogenesis Inhibition in Metastatic Prostate Cancer. *Adv Prostate Cancer* 1998;8:2-5.

Fuse E, Tannii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RM, Headlee D, **Figg WD**, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S. Unpredicted Clinical Pharmacology of UCN-01 Caused by Specific Binding to Human alpha1-acid glycoprotein. *Cancer Res* 1998;58:3248-53.

Bauer KC, Lush RM, Rudek MA, **Figg WD**. Novel Targets in Cancer Therapy: Angiogenesis, Matrix Metalloproteinase, Cyclin-Dependent Kinases, and Signal Transduction. *Highlights in Oncology Pract* 1998;16:3-11.

Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Steinberg S, **Figg WD**, Tompkins A, Arbuck S, Sausville EA. A Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-dependent Kinase Inhibitor, in Patients with Refractory Neoplasms. *J Clin Oncol* 1998;16:2986-99.

Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E, **Figg WD**. Pharmacokinetics and Relative Bioavailability of Carboxyamido-triazole with Respect to Food and Time of Administration: Use of a Single Model for Simultaneous Determination of Changing Parameters. *J Pharmacokin Biopharm* 1998;26:673-87.

Arah IN, Dixon SC, Horti J, **Figg WD**. Enhanced Activity of Estramustine, Vinblastine, Etoposide and Suramin in Prostate Carcinoma. *Neoplasma* 1999;46:117-23.

**Figg WD**, Pluda JM, Sartor O. Pentosan Polysulfate: A Polysaccharide that Inhibits Angiogenesis by Binding Growth Factors. In Teicher BA (Editor) Antiangiogenic Agents in Cancer Therapy. Published by Humana Press, Inc., Totowa, NJ, 1999;371-383.

Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, **Figg WD**. Increased Transcriptional Activity of Prostate Specific Antigen in the Presence of TNP-470, An Angiogenesis Inhibitor. *Br J Cancer* 1999;79:1588-93.

**Figg WD**, Reed E, Green S, Pluda JM. Thalidomide, A Prodrug Inhibits Angiogenesis. In Teicher BA (Editor) Antiangiogenic Agents in Cancer Therapy. Published by Humana Press, Inc., Totowa, NY, 1999;407-22.

Kang MH, **Figg WD**, Dahut W. Taxanes in Hormone Refractory Prostate Cancer. *Cancer Pract* 1999;7:270-2.

Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong WPY, Lim S, **Figg WD**. Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients with Recurrent Glioma. *Mayo Clin Proc* 1999;74:137-45.

Lush RM, Rudek MA, **Figg WD**. Review of Three New Agents that Target Angiogenesis, Matrix Metalloproteinases and Cyclin Dependent Kinases. *Cancer Control* 1999;6:459-465.

Melchior SW, Brown LG, **Figg WD**, Quinn JE, Santucci RA, Brunner J, Thuroff JW, Lange PH, Vessella RL. Effects of Phenylbutyrate on Proliferation and Apoptosis in Human Prostate Cancer Cells in vitro and in vivo.  *Int J Oncology* 1999;14:501-8.

Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, **Figg WD**, Tompkins A, Linehan WM, Kohler D, Steinberg SM, Blagosklonny MV. A Phase II Study of High Dose Tamoxifen in Patients with Hormone-Refractory Prostate Cancer. *Clin Cancer Res* 1999;5:2366-73.

Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, **Figg WD**. Therapy for Advanced Prostate Cancer with Granulocyte Macrophage Colony - Stimulating Factor. *Clin Cancer Res* 1999;5:1738-44.

Sartor O, **Figg WD**. Current Management of Hormone Refractory Prostate Cancer. In Woods DP, Honn KV (Editors) The Oncobiology of the Prostate, Vol. 3. Published by JAI Press, Inc., Stamford, CT, 1999;235-256.

Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM, Reed E, **Figg WD**, Sausville E. A Phase II Trial of Gallium Nitrate in Patients with Androgen Metastatic Prostate Cancer. *Urol Int* 1999;63:120-5.

**Figg WD**, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Pharmacokinetics of Thalidomide in an Elderly Prostate Cancer Population. *J Pharm Sci* 1999;88:121-5.

Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee KB, Venzon DJ, Bauer KS, Reed E, **Figg WD**. Pharmacokinetics of Cisplatin Administered by Continuous Hyperthermic Peritoneal Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. *J Clin Pharmacol* 1999;39:394-401.

Reed E, Matthews D, Dyer V, **Figg WD**. Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report. *The Prostate J* 1999;1:99-102.

**Figg WD**, Blumenfeld JR. Are We Making an Impact on Prostate Cancer? *Prostate Cancer and Prostatic Dis* 1999;2:60-61.

Dixon SC, Kruger EA, Bauer KS, **Figg WD**. Thalidomide Upregulates Prostate-Specific Antigen Secretion from LNCaP Cells. *Cancer Chemotherap Pharmacol* 1999;43:S78-84.

Sartor O, Rayford W, **Figg WD**. Management of Metastatic Prostate Cancer. In McConnell JD, Scardino PT (Editors) Atlas of Clinical Urology, Vol. II. The Prostate. Published by Current Medicine, Inc., Philadelphia, PA, 1999;15.1-15.14.

Park BJ, Brown CK, Hu Y, Alexander HR, Horti J, Raje S, **Figg WD**, Bartlett DL. Augmentation of Melanoma-Sp*Human Gene Therapy* 1999;10:889-98.

Cude KJ, Dixon SC, Guo Y, Lisella J, **Figg WD**. The Androgen Receptor: Genetic Considerations in the Development and Treatment of Prostate Cancer. *J Mol Medicine* 1999;77:419-26.

Luzzio FA, Piatt Zacherl D, **Figg WD**. A Facile Scheme for Phthalimide/Phthalimidine Conversion. *Tetrahedron Letters* 1999;40:2087-90.

Bauer KS, **Figg WD**, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda J, Reed E. A Pharmacokinetically Guided Phase II Study of Carboxyamido-triazole (CAI) in Androgen Independent Prostate Cancer. *Clin Cancer Res* 1999;5:2324-9.

Saif MW, **Figg WD**, Hewitt S, Brosky K, Reed E, Dahut W. Malignant Ascites as Only Manifestation of Metastatic Prostate Cancer. *Prostate Cancer Prostat Dis* 1999;2:290-3.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 1999;17:3461-7.

Erratum: Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen Independent Prostate Cancer: Recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* 2000;18:2644. Erratum: *J Clin Oncol* 2007;25:1154.

Kruger EA, Blagosklonny MV, Dixon SC, **Figg WD**. UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response. *Invasion Met* 2000;18:209-18.

Wilson WH, Sorbara L, **Figg WD**, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowitz A, Monks A. Modulation of Clinical Drug Resistance in a B-Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm. *Clin Cancer Res* 2000;6:415-21.

Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, **Figg, WD**. A High-Performance Liquid Chromatography Method using Ultraviolet and Fluorescence Detection for the Quantitation of UCN-01, 7-hydroxystaurosporine, from Human Plasma and Saliva. *Biomed Chromatogr* 2000;14:338-43.

Bauer KS, Cude KJ, Dixon SC, Kruger EA, **Figg WD**. Carboxyamido-Triazole Inhibits Angiogenesis by Blocking the Calcium-Mediated Nitric-Oxide Synthase-Vascular Endothelial Growth Factor Pathway. *J Pharmacol Exp Ther* 2000;292;31-7.

Kruger EA, Reed E, **Figg WD**. Thalidomide. In Rubanyi GM (Editor) Angiogenesis in Health and Disease. Published by Marcel Dekker Inc., New York, NY, 2000;359-376.

Blagosklonny MV, Dixon SC, **Figg WD**. Efficacy of Microtubule-active Drugs followed by Ketoconazole in Human Metastatic Prostate Cancer Cell Lines. *J Urol* 2000;163:1022-6.

Luzzio FA, Thomas EM, **Figg WD**. Thalidomide metabolites and analogs. Part II: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. *Tetrahedron Letters* 2000;41:7151-5.

Fine HA, **Figg WD**, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WKA. A Phase II Trial of the Anti-angiogenic Agent Thalidomide in Patients with Recurrent High Grade Gliomas. *J Clin Oncol* 2000;18:708-15.

Luzzio FA, Mayorov AV, **Figg WD**. Thalidomide Metabolites I: Derivatives of (+)-2-(N-Phthalimido)-gamma-hydroxyglutamic acid. *Tetrahedron Letters* 2000,41,2275-2278.

Kruger EA, Duray PH, Tsokos MG, Libutti S, Dixon SC, Rudek M, Pluda J, Allegra C, **Figg WD**. Endostatin Inhibits Microvessel Formation in the *ex vivo* Rat Aortic Ring Angiogenesis Assay. *Biochem Biophys Res Comm* 2000;268:183-91.

Rudek MA, March CL, Bauer KS, Pluda JM **Figg WD**. High-Performance Liquid Chromatography with Mass Spectrometry Dection for Quantitating COL-3, A Chemically modified Tetracycline, in Human plasma in Human. *J Pharmaceut Biomed Anal* 2000;22:1003-14.

Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, **Figg WD**. Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R. Activity of Thalidomide in AIDS-related Kaposi’s Sarcoma. *J Clin Oncol* 2000;18:2593-602.

Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, **Figg WD**, Grove A, Kohn E, Stern D, Libutti SK. Endothelial Monocyte Activating Polypeptide II induces Endothelial Cell Apoptosis and May Inhibit Tumor Angiogenesis. *Microvascular Res* 2000;60:70-80.

Berger AC, Feldman AL, Gnant MFX, Kruger EA, Sim BKL, **Figg WD**, Alexander HR, Libutti SK. The Angiogenesis Inhibitor, Endostatin Does Not Effect Murine Cutaneous Wound Healing. *J Surg Res* 2000;91:26-31.

Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, **Figg WD**, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe E, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. A Phase I study of combination therapy with immunotoxin IgG HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. *Clin Cancer Res* 2000:6:1302-13.

Kruger E, **Figg WD**. TNP-470: An Angiogenesis Inhibitor in Clinical Development for Cancer. *Exp Opin Investig Drugs* 2000;9:1383-1396.

Woo EW, Quinn M, **Figg WD**, Dahut W. The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. *Oncol Issues* 2000;15:23-27.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, **Figg WD**, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of Ligand Activation of peroxisome proliferators activated receptor on Human Prostate Cancer. *Proc Natl Acad Sci USA*  2000;97:10990-5.

Montgomery JS, **Figg WD**. The Essential Role of Apoptosis in Prostate Cancer Therapy. *Highlights in Oncol Pract* 2000:18:64-71.

Salnikow K, Costa M, **Figg WD**, Blagosklonny MV. Hyperinducibility of Hypoxia-Responsive Genes without p53/p21-dependent Checkpoint in Aggressive Prostate Cancer. *Cancer Res* 2000;60:5630-4.

Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, **Figg WD**, McLeod DG. Comparative Study of the Clinical Efficacy of Two Dosing Regimens of Flutamide. *Mol Urol* 2000;4:259-63.

Walther MM, Rehak NN, Venzon D, Myers CE, Linehan WM, **Figg WD**. Suramin Administration is Associated with a Decrease in Serum Calcium Levels. *World J Urol* 2000;18:388-91.

Blagosklonny MV, Dixon SC, Robey R, **Figg WD**. Resistance to growth inhibitory and Apoptotic Effects of Phorbol Ester and UCN01 in aggressive Cancer Cell Lines. *Int J Oncol* 2001;18:697-704.

Rochat B, Murray GI, **Figg WD**, McLeod HL. Human Cytochrome P450 1B1 and Anticancer Agent Metabolism: Mechanism for Tumor Specific Drug Inactivation? *J Pharmacol Exper Therapeut* 2001;296:537-41.

Montgomery JS, Price DK, **Figg WD**. The Androgen Receptor Gene and its Influence on the Development and Progression of Prostate Cancer. *J Pathology* 2001:195:138-46.

Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, **Figg WD**, Fojo T, Bates S. A Phase I Study of Infusional Paclitaxel in Combination with the p-glycoprotein Antagonist PSC833. *J Clin Oncol* 2001;19:832-42.

Dixon SC, Knopf KB, **Figg WD**. The Control of Prostate Specific Antigen Expression and Gene Regulation by Pharmacological Agents. *Pharmacol Rev* 2001;53:73-91.

Logothetis CJ, Wu KK, Finn LD, Daliani D, **Figg W**, Ghaddar H, Gutterman JU. Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-independent Prostate Cancer. *Clin Cancer Res* 2001;7:1198-1203.

Bartlett DL, Libutti SK, **Figg WD**, Fraker DL, Alexander HR. Isolated Hepatic Perfusion for Unresectable Hepatic Metastases from Colorectal Cancer.  *Surg* 2001;129:176-87.

Rudek MA, **Figg WD**, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer. *J Clin Oncol* 2001;19:584-92.

Burstein AH, Reed E, Tompkins AC, Venzon D, **Figg WD**. Phenylacetate Pharmacokinetics Based on Interactive Two-Stage Population Analysis. *Pharmacotherap* 2001;21:281-6.

Ghate JV, Turner ML, Rudek MA, **Figg WD**, Dahut W, Dyer V, Pluda JM, Reed E. Drug-Induced Lupus Associated with COL-3: A report of 3 cases. *Arch Dermatol* 2001;137:471-4.

**Figg WD**, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. *Semin Oncol* 2001;28(Suppl 15):62-66.

Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC, Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S, **Figg WD**, Cook JA, Mitchell JB, Van Waes C. Concurrent Paclitaxel and Radiation in the Treatment of Locally Advanced Head and Neck Cancer. *J Clin Oncol* 2001;19:800-11.

Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, **Figg WD**, Lahusen T, Jaken S, Jing XX, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase I Trial of 72 hour Continuous Infusion UCN-01 in Patients with Refractory Neoplasms. *J Clin Oncol* 2001;19:2319-2333.

Dahut WD, Fedenko KM, Noone M, Arlen P, Gulley J, Pluda J, **Figg WD**. A Randomized Phase II Trial of Docetaxel plus Thalidomide in Androgen-Independent Prostate Cancer. *Adv Prostate Cancer* 2001;5:8-10.

**Figg WD**, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon SC, Kohler DR, Kruger E, Gubish E, Pluda JM, Reed E. A Randomized Phase II Trial of Thalidomide, An Angiogenesis Inhibitor, in Patients with Androgen Independent Prostate Cancer. *Clin Cancer Res* 2001;7:1888-93.

Woo EW, Messmann R, Sausville EA, **Figg WD**. Quantitative Determination of Perifosine, a Novel Alkylphosphocholine Anticancer Agent, in Human Plasma by Reversed-Phase Liquid Chromatography - Electrospray Mass Spectrometry. *J Chromatogr B* 2001;759:247-57.

Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, **Figg WD**. Thalidomide neuropathy in patients treated for metastatic prostate cancer. *Muscle Nerve* 2001;24;1050-7.

Rudek MA, Horne M, **Figg WD**, Dahut W, Dyer V, Pluda JM, Reed E. Reversible Sideroblastic Anemia Associated with the Tetracycline Analog COL-3. *Am J Hematol* 2001;67:51-3.

Kang MH, **Figg WD**, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. The p-glycoprotein antagonist PSC 833 increases the Plasma concentrations of 6 alpha-hydroxypaclitaxel, a Major Metabolite of Paclitaxel. *Clin Cancer Res* 2001;7:1610-7.

Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, **Figg WD**, Liotta LA. A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination, and Demonstration of Pharmacokinetic Interaction. *Clin Cancer Res* 2001;7:1600-9.

Kruger EA, **Figg WD**. Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex vivo Rat Aortic Ring Angiogenesis Assay. *Clin Cancer Res* 2001;7:1867-72.

Kruger EA, Duray PH, Price DK, Pluda JM, **Figg WD**. Approaches to Preclinical Screening Antiangiogenic Agents. *Sem Oncol* 2001;28:570-576.

Bates S, Kang M, Meadows B, Bakke S, Meadows B, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, **Figg WD**, Fojo T. A Phase I Study of Infusional Vinblastine in Combination with the Pgp Antagonist PSC 833 (Valdospar). *Cancer* 2001;92:1577-1590.

Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, **Figg WD**. Bartlett DL. Laparoscopic Continuous Hyperthermic Peritoneal Perfusion. *J Am College of Surg* 2001;193:225-9

Gore SD, Weng LJ, Zhai S, **Figg WD**, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB. Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res* 2001;7:2330-9.

Carrasquillo JA, Whatley M, Dyer V, **Figg WD**, Dahut W. Alendronate does not interfere with 99m TC-methylene diphosphonate bone scanning. *J Nucl Med* 2001;42:1359-63.

Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, **Figg WD**, Rivera Y, Neckers L. The Hsp90 Inhibitor Geldanamycin Selectively Sensitizes Bcr-Abl-expressing Leukemia Cells to Cytotoxic Chemotherapy. *Leukemia* 2001;15:1537-43.

Gilbert J, Baker SD, Bowling MK, Grochow L, **Figg WD**, Zabelina Y, Donehower RC, Carducci MA. A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies. *Clin Cancer Res* 2001;7:2292-2300.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Update: Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer. *Classic Papers and Current Comments* 2001;6:311-7.

Schrump DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE, Flynn BM, Duray PH, **Figg WD**. Pharmacokinetics of Paclitaxel Administered by Hyperthermic Retrograde Isolated Lung Perfusion Techniques. *J Thorac and Cardiovascul Surg* 2002;123:686-694.

Arlen PM, **Figg WD**, Gulley J, Cox MC, Linehan WM, Dahut W. National Cancer Institute Intramural Approach to Advanced Prostate Cancer. *Clin Prostate Cancer* 2002;1:153-62.

Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, **Figg WD**, Krown SE, Dezube BJ. Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. *J Clin Oncol* 2002;20:153-159.

Bates SF, Chen C, Robey R, Kang M, **Figg WD**, Fojo T. Reversal of Multidrug Resistance: Lessons from Clinical Oncology. *Novartis Found Symp*. 2002;243:83-96; discussion 96-102, 180-5.

Kaur M, Reed E, Sartor O, Dahut W, **Figg WD**. Suramin's Development: What Did We Learn? *Invest New Drugs* 2002;20:209-219.

**Figg WD**, Kruger EA, Kim S, Price DK, and Dahut WD. Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer. *Invest New Drugs* 2002;20:183-94.

Price DK, Ando Y, Kruger EA, Weiss M, **Figg WD**. 5'-OH- Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis. *Therapeut Drug Monitoring* 2002;24:104-10.

Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, **Figg WD**. Antiangiogenesis Therapeutic Strategies in Prostate Cancer. *Cancer Metastasis Rev* 2002;21:93-106.

Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon D, Leiwher DJ, Johnson ME, Reed E, **Figg WD**. The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer. *Urol Int* 2002;68:16-23.

Ando Y, Fuse E, **Figg WD**. Thalidomide Metabolism by CYP2C subfamily. *Clin Cancer Res* 2002;8:1964-73.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, **Figg WD**, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. *Clin Cancer Res* 2002;8:718-28.

Zhai S, Senderowicz AM, Sausville EA, **Figg WD**. Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development. *Annals Pharmacother* 2002;36:905-11.

Zhai S, Sausville E, **Figg WD**. A High Performance Liquid Chromatography Method Using Ultraviolet Detection for the Quantitation of Flavopiridol from Human Plasma. *Biomedical Chromatogr* 2002;16:379-82.

Gore SD, Weng LJ, **Figg WD**, Zhai S, Donehower RC, Dover G, Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y, Miller CB. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res* 2002;8:963-970.

Neelapu S, **Figg WD**, Reed E. Leptomeningeal Carcinomatosis in Metastatic Prostate Cancer. *Southern Med J* 2002;95:107-8.

Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin MC, Courjal F, Ricard I, Poyet P, Falardeau P, **Figg WD**, Dupont E. The Antiangiogenic Agent Neovastat (AE-941) Inhibits Vascular Endothelial Growth Fractor-mediated Biological Effects. *Clin Cancer Res* 2002;8:1242-50.

Bennett CL, Price DK, Kim S, Liu D, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, **Figg WD**. Racial Variation in CAG repeat lengths within the Androgen Receptor gene among Prostate Cancer Patients of Lower Socioeconomic Status. *J Clin Oncol* 2002;20:3599-604.

Ando Y, **Figg WD**. Irinotecan in Small-Cell Lung Cancer. *New Engl J Med* (letter) 2002;346:1414-5.

Rudek MA, Venitz J, **Figg WD**. Matrix Metalloproteinase Inhibitors: Do they have a Place in the Anticancer Therapy? *Pharmacotherapy* 2002;22:705-720.

Ng SS, Brown M, **Figg WD**. Thalidomide, an Antiangiogenic Agent with Clinical Activity in Cancer. *Biomed Pharmacother* 2002;56:194-9.

Gulley J, **Figg WD**, Dahut WD. Docetaxel plus Thalidomide in a Patient with Androgen-Independent Prostate Cancer: Case Report. *Case Studies in Prostate Cancer* 2002;3;1-7.

Liu Y, **Figg WD**. Antiangiogenesis: Does it Have a Role in the Treatment of Metastatic Prostate Cancer? *Adv in Prostate Cancer* 2002;6:10-14.

Schrump DS, Nguyen DM, Kunst TE, Hancox A, **Figg WD**, Steinberg SM, Pishchik V, Becerra Y. Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients with Malignancies Involving Lungs or Pleura. *Clin Lung Cancer* 2002;4:186-92.

Ando Y, Price DK, Dahut WL, Cox MC, Reed E, **Figg WD**. Pharmacogenetic Associations of CYP2C19 Genotype with in vivo Metabolisms and Pharmacological Effects of Thalidomide. *Cancer Bio Ther*  2002;1:669-73.

Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, **Figg WD**, Wainer I, Chaissang C, Li MZ, Hawkins WJ. A Phase I trial of Depsipeptide (FR901228) in patients with Advanced Cancer. *J Experimental Therap Oncol* 2002;2:325-32.

Blagosklonny MV, Darzynkiewicz Z, **Figg WD**. Flavopiridol Inversely Affects p21(WAF1/CIP1) and p53 and Protects p21-Sensitive Cells from Paclitaxel. *Cancer Biol Ther* 2002;1:420-5.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, **Figg WD**, Swain SM, Senderowicz AM. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. *J Clin Oncol* 2002;20:4074-82.

Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, **Figg WD**, Alexander HR, Liu ET, Kohn EC, Libutti SK. Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay. *Biotechniques* 2002;33:664-70.

Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, Ding I, Headlee D, **Figg WD**, Sausville EA, Senderowicz AM. Flavopiridol-related Pro-inflammatory Syndrome Associated with Induction of Interleukin-6. *Clin Cancer Res* 2003;9:562-570.

Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo A, Melillo G, Fuse E, **Figg WD**. Clinical Pharmacology and Pharmacogenetics of Flavopiridol 1-Hour IV Infusion in Patients with Refractory Neoplasms. *AntiCancer Drugs* 2003;14:125-35.

Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, **Figg WD**, Purow BJ, Borkowf C. A Phase II Trial of Thalidomide and Carmustine for Patients with Recurrent High Grade Gliomas. *J Clin Oncol* 2003;21:2299-304.

Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, **Figg WD**. Current status of thalidomide and its role in the treatment of metastatic prostate cancer. *Critical Rev Oncol Hematol* 2003;46:Suppl 49-57.

Gulley JG, **Figg WD**, Dahut WL. Treatment options for Androgen Independent Prostate Cancer. *Clin Adv in Hematol and Oncol* 2003;1:49-57.

Lakhani NJ, Sarkar MA, Venitz J, **Figg WD**. 2-Methoxyestradiol, A Promising Anticancer Agent. *Pharmacotherapy* 2003;23:165-72.

Uchio EM, Linehan WM, **Figg WD**, Walther MM. A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. *J Urol* 2003;169:357-60.

Horne MK 3rd, **Figg WD**, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen Independent Prostate Cancer. *Pharmacotherapy* 2003;23:315-8.

Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D, Duray P, Liewehr DJ, Lakhani N, Steinberg SM, **Figg WD**, Reed E. A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen Independent Prostate Cancer. *Acta Oncol* 2003;42:195-201.

Leonard GD, Dahut WL, Gulley J, Arlen P, **Figg WD**. Docetaxel and Thalidomide as a Treatment Option in Androgen Independent Non-metastic Prostate Cancer. *Rev Urol* 2003;5(Suppl 3):S65-70.

Sparreboom A, Danesi R, Ando Y, Chan J, **Figg WD**. Pharmacogenomics of ABC Transporters and its Role in Cancer Chemotherapy. *Drug Resistance Updat* 2003;6:71-84.

Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, **Figg WD**. Clinical Pharmacology of Flavopiridol Following a 72-Hour Continuous Infusion. *Ann Pharmacother* 2003;37:1369-74.

Kurdziel KA, **Figg WD**, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL. Using Positron Emission Tomography 2-Deoxy-2-[18F] Fluro-D-Glucose, 11CO, and 15O-water for Monitoring Androgen Independent Prostate Cancer. *Mol Imaging Biol* 2003;5:86-93.

Luzzio FA, Mayorov AV, Ng SS, Kruger EA, **Figg WD**. Thalidomide Metabolites and Analogs. Part 3: Synthesis and Antiangiogenic Activity of the Teratogenic and TNFalpha-Modulatory Thalidomide Analog 2-(2,6-Dioxopiperidine-3-yl)phthalimidine. *J Med Chem* 2003;46:3793-9.

Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, **Figg WD**. Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. *J Clin Pharmacol* 2003;43:1124-35.

Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K**, Figg WD**. Antiangiogenic Activity of N-Substituted and Tetrafluorinated Thalidomide Analogues. *Cancer Res* 2003;63:3189-94.

Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, **Figg WD**. Anti-angiogenic activity of human endostatin is HIF-1- independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. *Mol Cancer Ther* 2003;2:845-54.

Lakhani NJ, Venitz J, **Figg WD**, Sparreboom A. Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer. *Curr Drug Metab* 2003;4:505-13.

Ng SS, **Figg WD**. Antitumor Activity of Herbal Supplements in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. *Anticancer Res* 2003;23:3585-90.

Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically Modified Tetracyclines as Matrix Metalloproteinase Inhibitors in Anti-Cancer Drug Development. In Mohan RM (Editor) Research Advances in Cancer, Vol 3, Part II, 2003. Published by Global Research Network, Kerala, India.

Lepper ER, Swain SM, Tan AR, **Figg WD**, Sparreboom A. Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor*. J Chromatogr B* 2003;796:181-8.

**Figg WD**, Cox MC. Pharmacy Education: Back to the Basics? *Pharmacotherapy* 2003;23:1381-90.

**Figg WD**, Cox MC. Pharmacy Education: Authors Response. *Pharmacotherapy* 2004;24:691-3.

Passaro MD, Piquion J, Mullen N, Sutherland D, Zhai S, **Figg WD**, Blye R, Nieman LK. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. *Hum Reprod*  2003;18:1820-1827.

ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, **Figg WD**, Sparreboom A. Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches. *Clin Pharmacol Ther* 2003;74:509-10.

Retter AS, **Figg WD**, Dahut WL. The Combination of Antiangiogenic and Cytotoxic Agents in the Treatment of Prostate Cancer. *Clin Prostate Cancer* 2003;2:153-9.

Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg S, Raggio M, Oliver VK, **Figg WD**, Kohn EC. A Phase II Trial of Carboxyamido-triazole in Patients with Relapsed Epithelial Ovarian Cancer. *J Clin Oncol* 2003;21:4356-63.

Macpherson GR, Ng SSW, Lakhani NJ, Price DK, Venitz J, **Figg WD**. Anti-angiogenesis Therapeutic Strategies in Prostate Cancer. In Cher ML, Honn KV, Raz A (Editors) Prostate Cancer: New Horizons in Research and Treatment. Published by Kluwer Academic Publishing, New York, NY, 2003, 317-331.

Franks ME, Macpherson GR, Lepper ER, **Figg WD**, Sparreboom A. New Directions in Cancer Research 2003: Technological Advances in Biology, Drug Resistance, and Molecular Pharmacology. *Drug Resist Updat* 2003;6:301-12.

Sparreboom A, Cox MC, Acharya MR, **Figg WD**. Herbal Remedies in the United States Potential Adverse Interactions with Anticancer Agents. *J Clin Oncol* 2004;22:2489-503.

Price DK, Franks ME, **Figg WD**. Genetic Variations in the Vitamin D Receptor, Androgen Receptor and Enzymes that Regulate Androgen Metabolism. *J Urol* 2004;171:S45-49.

Ehrlich A, Booher S, Becerra Y, Borris DL, **Figg WD**, Turner ML, Blauvelt A. Micellar Paclitaxel Improves Severe Psoriasis in a Prospective Phase II Pilot Study*. J Am Acad of Derm* 2004;50:533-40.

Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, **Figg WD**, Albert PS, Menard C, Camphausen K. Urinary VEGF and MMP levels as Predictive Markers of 1-year Progression-free Survivial in Cancer Patients Treated with Radiation Therapy: A longitudinal Study of Protein Kinetics throughout Tumor Progression and Therapy. *J Clin Oncol* 2004;22:499-506.

Franks ME, Macpherson GR, **Figg WD**. Thalidomide. *Lancet* 2004;363:1802-11.

**Figg WD**, McLeod HL (Editors) Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Published by Humana Press, Totowa, NJ, 2004.

Acharya MR, **Figg WD**. Book Review: Handbook of Pharmaceutical Biotechnology. *Annals of Pharmacotherapy* 2004;38:178.

Ng SS, **Figg WD**, Sparreboom A. Taxane-Mediated Antiangiogenesis In Vitro: Influence of Formulation Vehicles and Binding Proteins. *Cancer Res* 2004;64:821-4.

Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, **Figg WD**. A Phase I Study of Oral CC-5013 (lenalidomide, Revlimid), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer. *Clin Prostate Cancer* 2004;2:241-3.

Cox MC, **Figg WD**, Thurman PW. No Rational Theory for Drug Pricing. *J Clin Oncol* 2004;22;962-3.

Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW**, Figg WD**, Sparreboom A. Determination of MS-275, a Novel Histone Deacetylase Inhibitor, in Human Plasma by Liquid Chromatography-Electrospray Mass Spectrometry. *J Chromatogr B* 2004;804:289-94.

McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, **Figg WD**, Folkman J, Hanahan D, Auerbach R, O’Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the Society for Biological Therapy and Vascular Biology Faculty of the NCI Workshop on Angiogenesis Monitoring. *J Immunonotherap* 2004;27:161-175.

Luzzio FA, **Figg WD**. Thalidomide Analogues: Derivatives of an Orphan Drug with Diverse Biological Activity. *Expert Opinion on Therapeutic Patents* 2004;14:215-29.

**Figg WD**, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van-Bingham W, Eastham JA, Reed E, Sartor O. Gleason Score and Pretreatment PSA in Survival Amoung Patients with Stage D2 Prostate Cancer. *World J Urol* 2004;22:425-30.

Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Parr AL, **Figg WD**, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. Evaluation of Biologic End Points and Pharmacokinetics in Patients with Metastatic Breast Cancer after Treatment with Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. *J Clin Oncol*, 2004;22:3080-90.

Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, **Figg WD**. Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors. *J Med Chem* 2004;47:2219-27.

Tohnya TM, Kim S, Fine HA, Dunn L, **Figg WD**, Sparreboom A. Determination of SU5416, a Novel Angiogenesis Inhibitor, in Human Plasma by Liquid Chromatography. *J Chromatogr B* 2004;805;135-40.

Singh A, **Figg WD**. Upregulation of the Androgen Receptor During Prostate Cancer Progression. *Cancer Biol Therapy* 2004;3:284-5.

Lepper ER, Hicks JK, Verweij J, Zhai S, **Figg WD,** Sparreboom A. Determination of Midazolam in Human Plasma by liquid chromatography with mass-spectrometric detection. *J Chromatogr B* 2004;806:305-10.

Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, **Figg WD**. Determination of the Antiangiogenesis Agent 2-Methoxyestradiol (2ME2) in Human Plasma by Liquid Chromatography with Ultraviolet Detection. *J Chromatogr B* 2004;806:289-93.

Ng SS, Macpherson GR, Gutschow M, Eger K, **Figg WD**. Antitumor Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice. *Clin Cancer Res* 2004;10:4192-7.

Acharya MR, Baker SD, Verweij J, **Figg WD**, Sparreboom A. Determination of fraction unbound docetaxel using microequilibrium dialysis. *Anal Biochem* 2004;331:192-4.

Acharya MR, Venitz J, **Figg WD**. What Dose do you Start with and How Quickly do you Increase that Dose? *Am Pharmaceutic Outsourcing* 2004;5:1-4.

Cox MC, Smith NF, **Figg WD**. The Use of Thalidomide in Renal Cancer. *American Society of Clinical Oncology 2004 Educational Book* 2004;249-51

Price DK, **Figg WD**. H-Tert-Immortalized Endothelial Cells: An Important New Research Tool. *Cell Cycle* 2004;3:789.

Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, **Figg WD**. A Randomized Phase II Trial of Docetaxel plus Thalidomide in Androgen-Independent Prostate Cancer*. J Clin Oncol* 2004;22:2532-9.

Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, **Figg WD**, Fojo T. A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC-833) in Renal Cell Carcinoma. *Clin Cancer Res* 2004;10:4724-33.

Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, **Figg WD**, Swain SM. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer. *Clin Cancer Res* 2004;10:5038-47.

Cox M, Liu Y, **Figg WD**. Antiangiogenesis in Prostate Cancer. *Cancer Therapy* 2004;2:121-9.

Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically modified Tetracyclines as Inhibitors of Matrix Metalloproteinases. *Drug Resist Updat* 2004;7:195-208.

Paoluzzi L, **Figg WD**. Histone Deacetylase Inhibitors are Potent Radiation Protectants. *Cancer Biol Ther* 2004;3:612-3.

Macpherson G, **Figg WD**. Small molecule-mediated anti-cancer therapy via hypoxia inducible factor-1 blockade. *Cancer Biol The* 2004;3:503-4.

Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, **Figg WD**, Sparreboom A. Influence of genetic variants in *UGT1A1* and *UGT1A9* on the *in vivo* glucuronidation of SN-38. *J Clin Pharmacol* 2004;44:854-60.

Hwang K, Piekarz RL, Bates SE, **Figg WD**, Sparreboom A. Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry. *J Chromatogr B* 2004;809:81-86.

Price DK, **Figg WD**. Mutations in the EGFR: The Importance of Genotyping. *Cancer Bio Ther* 2004;3:434-5.

Mathijssen RHJ, De Jong FA, Van Schaik RHN, Lepper ER, Friberg L, Rietveld T, De Bruijn P, Graveland WJ, **Figg WD**, Verweij J, Sparreboom A. Prediction of Irinotecan Pharmacokinetics by use of Cytochrome P4503A4 Phenotyping Probes. *J Natl Canc Inst,* 2004;96:1585-92.

Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon D, Margo A, Headlee D, Sausville EA, Effects of Alpha1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-hydroxystaurosporine. **Figg WD**. *Clin Cancer Res* 2004;10:6840-6.

Ng SSW, **Figg WD**. Upregulation of Endogenous Angiogenesis Inhibitors: A Mechanism of Action of Metronomic Chemotherapy. *Cancer Biol Therapy* 2004;3:1212-3.

Acharya MR, **Figg WD**. Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue. *Cancer Bio Therapy* 2004;3:719-20.

Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J, Sparreboom A, **Figg WD**. Determination of CC-5013, a Thalidomide Analogue, in Human plasma by liquid Chromatography-mass Spectrometry. *J Chromatogr B* 2004;811:135-41.

Smith NF, **Figg WD**, Sparreboom A. Recent Advances in Pharmacogenetic Approaches to Anti-Cancer Drug Development. *Drug Develop Res* 2004;51:1-21.

Retter AS, **Figg WD**, Dahut WL. A Case Study of Docetaxel and Thalidomide in Androgen Independent Prostate Cancer. *Am J of Oncol Rev* 2004;3:618-21.

Cox MC, Lepper ER, **Figg WD**, Sparreboom A. Use of St. John’s Wort by Cancer Patients: Novel Insights and Safety Considerations. *J Cancer Integrative Med* 2004;2:125-136.

Macpherson GR, Singh A, Bennett C, Venzon D, Liewehr D, Franks M, Dahut B, Price DK, **Figg WD**. Genotypic and functional analysis of the D104N variant of Human Endostatin. *Cancer Bio Therap* 2004;3:1298-303.

Tohnya TM, **Figg WD**. Immunomodulation of Multiple Myeloma. *Cancer Bio Therapy* 2004;3:1060-1.

Baker SD, Li J, ten Tije AJ, **Figg WD**, Graveland W, Verweij J, Sparreboom A. Relationship of systemic Exposure to Unbound Docetaxel and Neutropenia. *Clin Pharmacol Ther* 2005;77:43-53.

**Figg WD**, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Co